Time to progression is the main predictor of survival in patients with high-risk nonmuscle invasive bladder cancer: Results from a machine learning-based analysis of a large multi-institutional database

CONCLUSION: Time to progression is the main predictor of OS in patients with high risk NMIBC treated with BCG and might be considered a coprimary endpoint. In addition, models including time to progression could be considered for patients' stratification in clinical practice and at the time of clinical trials design.PMID:38302296 | DOI:10.1016/j.urolonc.2024.01.001

Source: Urologic Oncology - February 1, 2024 Category: Urology & Nephrology Authors: Annamaria Porreca Marta Di Nicola Giuseppe Lucarelli Vartolomei Mihai Dorin Francesco Soria Daniela Terracciano Francesco Alessandro Mistretta Stefano Luzzago Carlo Buonerba Francesco Cantiello Andrea Mari Andrea Minervini Alessandro Veccia Alessandro Ant Source Type: research